

Resource Summary Report

Generated by T1D on Aug 9, 2026

HOMA2 calculator

RRID:SCR_023419

Type: Tool

Proper Citation

HOMA2 calculator (RRID:SCR_023419)

Resource Information

URL: <https://www.dtu.ox.ac.uk/homacalculator/>

Proper Citation: HOMA2 calculator (RRID:SCR_023419)

Description: Software tool used to calculate Homeostasis Model Assessment which takes account of variations in hepatic and peripheral glucose resistance, increases in insulin secretion curve for plasma glucose concentrations and contribution of circulating proinsulin. Provides access to HOMA2 model for researchers who wish to use model derived estimates of %B and %S, rather than linear approximations.

Synonyms: HOMA Calculator

Resource Type: software resource, software application

Keywords: calculate Homeostasis Model Assessment, Homeostasis Model Assessment, HOMA calculator

Availability: Free, Available for download, Freely available

Resource Name: HOMA2 calculator

Resource ID: SCR_023419

Record Creation Time: 20230328T050203+0000

Record Last Update: 20260808T190534+0000

Ratings and Alerts

No rating or validation information has been found for HOMA2 calculator.

No alerts have been found for HOMA2 calculator.

Data and Source Information

Usage and Citation Metrics

We found 81 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Yang Y, et al. (2026) Associations of time in tight range, time in range, and glycated hemoglobin with albuminuria and diabetic kidney disease in adult type 2 diabetes: a cross-sectional study. BMC endocrine disorders, 26(1).

Yang Y, et al. (2026) Continuous glucose monitoring-derived glycemic variability and low skeletal muscle mass in middle-aged and older adults with type 2 diabetes mellitus: an analysis using AWGS 2025 criteria. Diabetology & metabolic syndrome, 18(1).

Paudel P, et al. (2026) Reference intervals for fasting insulin and insulin-related indices in healthy adults: a cross-sectional study in Gandaki Province, Nepal. BMJ open, 16(3), e109523.

Li C, et al. (2026) Serum 25-hydroxyvitamin D levels and their association with ketosis in patients with newly diagnosed type 2 diabetes. Medicine, 105(17), e48304.

Mellergaard M, et al. (2026) Circulating Liver-Derived and CD36+ Extracellular Vesicles Correlate With Ectopic Liver Fat and Markers of Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease and Decrease During Weight Loss Intervention. Journal of extracellular vesicles, 15(3), e70257.

Bhaganagarapu LS, et al. (2026) Bridging Glycemic and Lipid Control: Effects of Dapagliflozin in Co-Morbid Diabetes and Heart Failure - A Randomized Controlled Trial. Endocrine, metabolic & immune disorders drug targets, 26.

Chen C, et al. (2026) Clustering-based subgroups of type 2 diabetes mellitus and their associations with diabetes remission after bariatric surgery. Chinese medical journal, 139(1), 145.

Zheng H, et al. (2026) Insights on accelerometer-measured 24-hour movement behaviour across type 2 diabetes sub-phenotypes in the Asian population. Diabetes & vascular disease research, 23(2), 14791641261431769.

Decarnoncle M, et al. (2026) Effects of NAD⁺ repletion with Nicotinamide riboside on obesity-induced chronic kidney disease and renal cell lipotoxicity. Scientific reports, 16(1).

Li Z, et al. (2026) Hybrid PET/fMRI reveals interactive effects of T2DM and MCI on cerebral glucose metabolism and ALFF. Frontiers in endocrinology, 17, 1778600.

Boige V, et al. (2026) Circulating Tumor DNA Dynamics and Clinical Outcomes in Patients with Advanced Colorectal Cancer Treated with Cetuximab-Based Induction and Maintenance Treatment. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(10), 2088.

Almotairi R, et al. (2025) Evaluating the Impact of rs4025935, rs71748309, rs699947, and rs4646994 Genetic Determinants on Polycystic Ovary Syndrome Predisposition-A Case-Control Study. *Life (Basel, Switzerland)*, 15(4).

Roca Suarez AA, et al. (2025) Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver disease. *eGastroenterology*, 3(1), e100159.

Galderisi A, et al. (2025) Metabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of β Cell Function. *The Journal of clinical endocrinology and metabolism*, 110(11), 3168.

Aliyu U, et al. (2025) Genetic risk and polygenic risk score assessment of prediabetes and progression to type 2 diabetes. *Diabetes, obesity & metabolism*, 27(8), 4469.

Tas E, et al. (2025) The association between hepatic steatosis, vitamin D status, and insulin resistance in adolescents with obesity. *Obesity pillars*, 14, 100173.

Liweleya S, et al. (2025) Metabolic and inflammatory axes of insulin resistance in normoglycemic adults with high HIV burden. *PLOS global public health*, 6(1), e0005589.

Jagannathan R, et al. (2025) Subtypes of Type 2 Diabetes and Prediabetes: Mortality and Excess Life Lost in South Asians. *Research square*.

Shen X, et al. (2025) Cerebral Small Vessel Disease Outperforms Brain Atrophy as an Imaging Biomarker in Diabetic Retinopathy. *Journal of diabetes*, 17(2), e70058.

Askeland A, et al. (2025) Non-invasive liver fibrosis markers are increased in obese individuals with non-alcoholic fatty liver disease and the metabolic syndrome. *Scientific reports*, 15(1), 10652.